Adam Gold, PhD

Title: Medical Science Liasion

Organization: NS Pharma

2023 FUTURES: RNA targeted Therapeutics Sessions Part 1

A brief primer on the RNA-targetd therapeutic approach to treating Duchenne, and updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

Adam Gold, PhD

Medical Science Liasion

NS Pharma

Kevin Flanigan, MD

Director, Center for Gene Therapy Nationwide Children's Hospital

Karin Lucas, Ph.D

West Medical Science Liaison Team Lead, Global Medical Affairs Sarepta Therapeutics

Christian Werner, MD

Executive Director, Global Medical Affairs, and Global Duchenne Muscular Dystrophy Lead PTC Therapeutics